JBT Marel Posts Higher Profit as Protein Segment Offsets Impairment

The Tip Desk · August 3, 2026 · 2 min read

JBT Marel (JBTM) swung to a $28 million second-quarter profit despite a $33 million non-cash impairment charge, as orders climbed to $1.03 billion and backlog rose to $1.536 billion.

JBT Marel (JBTM) reported second-quarter net income of $28 million, up from $3 million a year earlier, even as the food-processing and packaging equipment maker absorbed a $33 million non-cash impairment charge during the period.

The increase came alongside a 5% rise in revenue to $981 million from $935 million, roughly 2 percentage points of which reflected foreign-exchange translation. Diluted earnings per share reached $0.54, compared with $0.07 in the prior-year quarter, while adjusted EPS rose to $1.95 from $1.49. Net income margin improved 250 basis points to 2.9%, and adjusted EBITDA climbed to $168 million from $156 million, lifting adjusted EBITDA margin 40 basis points to 17.1%.

Gross profit margin widened to 36.6% from 35.8%, but operating income margin compressed to 4.7% from 5.1%, a gap that traces back to the impairment charge and to uneven performance across the company's two segments.

Protein Solutions carried the quarter. Segment revenue rose 11% to $467 million from $421 million, and segment adjusted EBITDA margin expanded 350 basis points to 24.0%. Prepared Food and Beverage Solutions moved in the opposite direction: revenue held flat at $514 million even with a roughly 2% currency tailwind, and segment adjusted EBITDA margin slipped 70 basis points to 17.5%. The decline was due to logistics constraints and productivity inefficiencies tied to supply-chain and manufacturing optimization work.

Demand indicators pointed higher than the revenue print. Orders totaled $1.03 billion, up from $938 million a year earlier and including about $16 million of FX benefit, producing a book-to-bill ratio of 1.05x. Backlog closed the quarter at $1.536 billion, up from $1.394 billion a year earlier, giving the company a larger order cushion heading into the back half of the year.

JBT Marel reiterated full-year 2026 revenue guidance of $3,990 million to $4,065 million and adjusted EBITDA margin guidance of 17.0% to 17.5%. Adjusted EPS guidance was refined to reflect updated depreciation and amortization and tax-rate assumptions, while GAAP EPS and net income margin guidance were lowered to account for the second-quarter impairment charge.

Net debt fell to $1,586 million from $1,810 million a year earlier and $1,714 million at the prior year-end, bringing the leverage ratio to 2.47x, just below the company's 2.0x-to-2.5x long-term target.

The company also repurchased about 200,000 shares for $26 million during the quarter under a newly authorized $200 million buyback program running from May 18, 2026 through May 31, 2029, marking the start of capital return activity that had no counterpart in the prior comparison period.